Tilray Brands (TLRY) Non Operating Investment Income (2019 - 2026)
Tilray Brands (TLRY) posted Non Operating Investment Income of -$4.1 million for Q1 2026, down 1100.87% on a QoQ basis from -$345000.0 in Q4 2025, and up 24.31% year-over-year from -$3.3 million in Q1 2025.
Tilray Brands (TLRY) Non Operating Investment Income (2019 - 2026) Analysis & Trends
Tilray Brands' Non Operating Investment Income history runs 8 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- Quarterly Non Operating Investment Income rose 24.31% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$9.9 million (down 80.19% YoY) and the FY2022 annual result came in at -$6.7 million, down 186.44% from the prior year.
- Non Operating Investment Income was -$4.1 million for Q1 2026 at Tilray Brands, down from -$345000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $459000.0 in Q4 2023 and bottomed at -$5.5 million in Q1 2025.
- A 5-year average of -$1.2 million and a median of -$345000.0 in 2025 frame the typical range for Non Operating Investment Income.
- Peak annual rise in Non Operating Investment Income reached 200.0% in 2025, while the deepest fall reached 16687.88% in 2025.
- Tilray Brands' Non Operating Investment Income stood at -$596000.0 in 2022, then jumped by 177.01% to $459000.0 in 2023, then slumped by 105.88% to -$27000.0 in 2024, then sank by 1177.78% to -$345000.0 in 2025, then sank by 1100.87% to -$4.1 million in 2026.
- Business Quant data shows TLRY's Non Operating Investment Income at -$4.1 million in Q1 2026, -$345000.0 in Q4 2025, and $39000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | -4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -4.14 Mn |
| Feb 28, 2026 | -4.14 Mn |
| Nov 30, 2025 | -345,000.00 |
| Nov 30, 2025 | -345,000.00 |
| Aug 31, 2025 | 39,000.00 |
| Aug 31, 2025 | 39,000.00 |
| Feb 28, 2025 | -5.47 Mn |
| Feb 28, 2025 | -5.47 Mn |
| Nov 30, 2024 | -27,000.00 |
| Nov 30, 2024 | -27,000.00 |
| Aug 31, 2024 | -39,000.00 |
| Aug 31, 2024 | -39,000.00 |
| Feb 29, 2024 | 33,000.00 |
| Feb 29, 2024 | 33,000.00 |
| Nov 30, 2023 | 459,000.00 |
| Nov 30, 2023 | 459,000.00 |
| Feb 28, 2023 | -925,000.00 |
| Feb 28, 2023 | -925,000.00 |
| Nov 30, 2022 | -596,000.00 |
| Nov 30, 2022 | -596,000.00 |